PHAXIAM Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO PHAXIAM Therapeutics is Thibaut Fayet, benoemd in Jun2023, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt € 391.73K, bestaande uit 34.5% salaris en 65.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.055% van de aandelen van het bedrijf, ter waarde € 8.72K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 11.5 jaar.

Belangrijke informatie

Thibaut Fayet

Algemeen directeur

€391.7k

Totale compensatie

Percentage CEO-salaris	34.5%
Dienstverband CEO	1.4yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	11.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thibaut Fayet's beloning veranderd ten opzichte van PHAXIAM Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€22m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€392k	€135k	-€23m

Compensatie versus markt: De totale vergoeding ($USD 413.43K ) Thibaut } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 359.47K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Thibaut te vergelijken met de prestaties van het bedrijf.

CEO

Thibaut Fayet (56 yo)

1.4yrs

Tenure

€391,725

Compensatie

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Thibaut Fayet	Chief Executive Officer	1.4yrs	€391.73k	0.055% € 8.7k
Jérôme Bailly	Deputy CEO	4.8yrs	€262.41k	0.0038% € 601.8
Frédéric Mathat	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Cindy Fevre	Chief Scientific Officer	1.8yrs	geen gegevens	geen gegevens
Naomi Eichenbaum	Director Investor Relations	no data	geen gegevens	geen gegevens
Pascal Birman	Chief Medical Officer	1.4yrs	geen gegevens	geen gegevens
Philip Lorenzi	Consultant & Member of Scientific Board	no data	geen gegevens	geen gegevens
Eric Raymond	Consultant & Member of Scientific Board	no data	geen gegevens	geen gegevens
Bridget Bax	Consultant & Member of Scientific Board	no data	geen gegevens	geen gegevens
Arthur Frankel	Consultant & Member of Scientific Board	no data	geen gegevens	geen gegevens
Kurt Gunter	Consultant & Member of Scientific Board	no data	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0QSS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Lorenzi	Consultant & Member of Scientific Board	14.8yrs	geen gegevens	geen gegevens
Eric Raymond	Consultant & Member of Scientific Board	15.1yrs	geen gegevens	geen gegevens
Bridget Bax	Consultant & Member of Scientific Board	12.8yrs	geen gegevens	geen gegevens
Arthur Frankel	Consultant & Member of Scientific Board	12.8yrs	geen gegevens	geen gegevens
Kurt Gunter	Consultant & Member of Scientific Board	12.8yrs	geen gegevens	geen gegevens
Philippe Archinard	Independent Director	11.5yrs	€68.00k	0.010% € 1.6k
Gil Beyen	Vice Chairman	11.5yrs	€1.00m	0.0048% € 769.0
Hilde Windels	Independent Director	10.2yrs	€56.75k	geen gegevens
Didier Hoch	Chairman of the Board	1.4yrs	€153.18k	geen gegevens
Leila Nicolas	Representative Director	1.4yrs	€26.25k	geen gegevens
Robert Sebbag	Independent Director	1.4yrs	€21.75k	geen gegevens
Valerie Faillat	Independent Director	less than a year	geen gegevens	geen gegevens

11.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0QSS zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.5 jaar).

PHAXIAM Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

No longer forecast to breakeven

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

No longer forecast to breakeven

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

New 90-day low: €6.70

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

New 90-day high: €8.80

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

New 90-day high: €8.07

New 90-day high: €6.55

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd